Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Anavex Life Sciences Corp.NASDAQ: AVXL
Selling, General & Admin · Q1 FY2026 · quarter ended Dec 2025
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $2.13M fell 32.4% year over year, behind the +10.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 40.1% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $0 (-100.0%) for the fiscal year ending Sep 2026, a slowdown from the +25.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- $2.13M-40.1% QoQ
- Last fiscal yearSep 2025
- $13.82M+25.2% YoY
- LTMDec 2025
- $12.8M+10.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -32.4% | -100.0% | -67.6 pp |
| 1 year | +25.2% | -100.0% | -125.2 pp |
| 3-year CAGR | +1.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 13.82M USD
- Year-over-year change
- +25.2%
- 4-year CAGR
- +11.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 13.82M | +25.2% |
| FY2024 | 2024-09-30 | 11.04M | -8.4% |
| FY2023 | 2023-09-30 | 12.05M | -7.8% |
| FY2022 | 2022-09-30 | 13.07M | +44.9% |
| FY2021 | 2021-09-30 | 9.02M | — |
Selling, General & Admin vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.2% is the 5th highest of 10, against a peer median of +6.5%.
- Over three fiscal years its annual growth of +1.9% compares with a peer median of +4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.5M USD | -47.9% | +3.9% | 96.8% | |
| LTM Mar 2026 | $83.82M USD | +6.5% | -1.0% | 95.4% | |
| LTM Mar 2026 | €70.46M EUR | -23.0% | +9.1% | 45.1% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $59.07M USD | +263.5% | +71.2% | — |
| LTM Mar 2026 | $52.46M USD | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $46.46M USD | +34.5% | +22.2% | — | |
| LTM Sep 2026 | $44.05M USD | +16.1% | +5.3% | — | |
| LTM Mar 2026 | $31.1M USD | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $17.68M USD | +91.0% | — | 962.7% | |
| LTM Dec 2025 | $12.8M USD | +10.2% | +1.9% | — | |
| Peer median (excluding AVXL) | — | +6.5% | +4.8% | 91.5% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
| Selling, General & Admin | 9.02M | 13.07M | 12.05M | 11.04M | 13.82M |
| Operating Expenses | 42M | 50.99M | 55.76M | 52.88M | 51.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (37.64M) | (47.62M) | (46.54M) | (43M) | (46.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (42M) | (50.99M) | (55.76M) | (52.88M) | (51.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 26K | 947K | 6.52M | 7.32M | 4.68M |
| Interest Expense | 0 | 0 | 964K | 0 | 0 |
| Other Income / Expenses | 4.36M | 3.37M | 8.26M | 9.88M | 5.03M |
| Income Before Tax | (37.64M) | (47.62M) | (47.51M) | (43M) | (46.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 268K | 358K | 0 | 0 | 0 |
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| EPS (Diluted) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| Weighted Avg Shares | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
| Weighted Avg Shares (Diluted) | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.